Engineered immune cells delivered directly to the brain show promise for kids with deadly tumors

NCT ID NCT05835687

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment for children and young adults up to age 21 with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called B7-H3 found on tumor cells. These cells are delivered directly into the fluid around the brain through a small tube. The main goal is to find the safest dose and see if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor central nervous system cancer central nervous system neoplasm diffuse intrinsic pontine glioma diffuse midline glioma, H3 K27M-mutant ependymoma glioblastoma glioma malignant glioma medulloblastoma primary brain neoplasm rhabdoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••